-transparent.png){kind=logo}
Design, synthesis and biological evaluation of 6-chloro-quinolin-2-one derivatives as novel FXIa inhibitors. 2024
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
Tianjin Key Laboratory of Molecular Design and Drug Discovery, Puchuang Pharmaceutical Technology (Tianjin) Co., Ltd, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China; National Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, Tianjin Institute of Pharmaceutical Research, 306 Huiren Road, Tianjin 300301, PR China.
A series of 6-chloro-quinolin-2-one derivatives were designed and synthesized as FXIa inhibitors by exploration of P1, P1 prime and P2 prime groups. Each compound was accessed for inhibitory effect on FXIa and some of them were evaluated in the clotting assay. 14c demonstrated excellent in-vitro potency (FXIa IC50: 15 nM, 2 x aPTT: 6.8 μM) and good in-vivo efficacy (prolonged in-vivo aPTT by more than 1-fold but not PT). Moreover, the pharmacokinetics property of 14c were evaluated following intravenous administration in rats, which indicated that 14c probably will be a clinical candidate for intravenous administration.
| UI | MeSH Term | Description | Entries |
|---|
Related Publications
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
April 2022,
European journal of medicinal chemistry,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
October 2007,
Bioorganic & medicinal chemistry letters,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
October 2019,
European journal of medicinal chemistry,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
January 2010,
Bioorganic & medicinal chemistry,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
January 2018,
Current pharmaceutical design,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
May 2023,
European journal of medicinal chemistry,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
May 2010,
ChemMedChem,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
December 2020,
European journal of medicinal chemistry,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
January 2012,
Acta crystallographica. Section E, Structure reports online,
Yanshi Wang, and
Jianglin Yuan, and
Sida Yan, and
Peng Liu, and
Zhichao Zheng, and
Shijun Zhang, and
Fancui Meng, and
Wei Liu, and
Changjiang Huang, and
Qunchao Wei
May 2021,
International journal of molecular sciences,
